Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic

Cell Rep. 2016 Feb 16;14(6):1477-1487. doi: 10.1016/j.celrep.2015.12.105. Epub 2016 Jan 28.

Abstract

We have developed a Drosophila lung cancer model by targeting Ras1(G12V)--alone or in combination with PTEN knockdown--to the Drosophila tracheal system. This led to overproliferation of tracheal tissue, formation of tumor-like growths, and animal lethality. Screening a library of FDA-approved drugs identified several that improved overall animal survival. We explored two hits: the MEK inhibitor trametinib and the HMG-CoA reductase inhibitor fluvastatin. Oral administration of these drugs inhibited Ras and PI3K pathway activity, respectively; in addition, fluvastatin inhibited protein prenylation downstream of HMG-CoA reductase to promote survival. Combining drugs led to synergistic suppression of tumor formation and rescue lethality; similar synergy was observed in human A549 lung adenocarcinoma cells. Notably, fluvastatin acted both within transformed cells and also to reduce whole-body trametinib toxicity in flies. Our work supports and provides further context for exploring the potential of combining statins with MAPK inhibitors such as trametinib to improve overall therapeutic index.

Keywords: Drosophila; fluvastatin; non-small-cell lung cancer; trachea; trametinib.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Disease Models, Animal
  • Drosophila Proteins / antagonists & inhibitors
  • Drosophila Proteins / genetics
  • Drosophila Proteins / metabolism
  • Drosophila melanogaster / drug effects
  • Drosophila melanogaster / genetics
  • Drosophila melanogaster / metabolism
  • Drug Combinations
  • Drug Screening Assays, Antitumor / methods*
  • Drug Synergism
  • Fatty Acids, Monounsaturated / pharmacology*
  • Fluvastatin
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • IMP Dehydrogenase / antagonists & inhibitors
  • IMP Dehydrogenase / genetics
  • IMP Dehydrogenase / metabolism
  • Indoles / pharmacology*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • PTEN Phosphohydrolase / antagonists & inhibitors
  • PTEN Phosphohydrolase / genetics
  • PTEN Phosphohydrolase / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Pyridones / pharmacology*
  • Pyrimidinones / pharmacology*
  • Signal Transduction
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Drosophila Proteins
  • Drug Combinations
  • Fatty Acids, Monounsaturated
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Indoles
  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • trametinib
  • Fluvastatin
  • IMP Dehydrogenase
  • ras protein, Drosophila
  • PTEN Phosphohydrolase
  • PTEN protein, Drosophila